Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R.

J Clin Oncol. 2010 Aug 10;28(23):3701-8. doi: 10.1200/JCO.2009.27.2377. Epub 2010 Jul 12.

PMID:
20625121
2.

Siltuximab: a new option for the management of Castleman's disease.

Barquero N.

Drugs Today (Barc). 2015 Jan;51(1):21-8. doi: 10.1358/dot.2015.51.1.2234002. Review.

PMID:
25685858
3.

Cutaneous castleman's disease responds to anti interleukin-6 treatment.

Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R.

Mol Cancer Ther. 2007 Sep;6(9):2386-90. Epub 2007 Aug 31.

4.

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K.

Blood. 2000 Jan 1;95(1):56-61.

5.

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C.

Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17. Erratum in: Lancet Oncol. 2014 Sep;15(10):417.

PMID:
25042199
7.

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B.

N Engl J Med. 1994 Mar 3;330(9):602-5. No abstract available.

8.

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.

van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.

Oncotarget. 2015 Oct 6;6(30):30408-19. doi: 10.18632/oncotarget.4655.

9.

Siltuximab: first global approval.

Markham A, Patel T.

Drugs. 2014 Jul;74(10):1147-52. doi: 10.1007/s40265-014-0249-x. Review.

PMID:
24958337
10.

Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.

Mohammed A, Janku F, Qi M, Kurzrock R.

J Med Case Rep. 2015 Feb 28;9:45. doi: 10.1186/s13256-015-0517-8.

11.

Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.

Newsom-Davis T, Bower M, Wildfire A, Thirlwell C, Nelson M, Gazzard B, Stebbing J.

Leuk Lymphoma. 2004 Sep;45(9):1939-41.

PMID:
15223659
12.

Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice.

Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y.

Cytokine. 2002 Dec 21;20(6):304-11.

PMID:
12633573
13.

Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.

van Rhee F, Rothman M, Ho KF, Fleming S, Wong RS, Fosså A, Dispenzieri A, Cavet J, Munshi N, Vermeulen J, Casper C.

Patient. 2015 Apr;8(2):207-16. doi: 10.1007/s40271-015-0120-5.

14.

Clinical development of siltuximab.

Davis CC, Shah KS, Lechowicz MJ.

Curr Oncol Rep. 2015 Jul;17(7):29. doi: 10.1007/s11912-015-0453-1. Review.

PMID:
25986720
15.

Siltuximab for multicentric Castleman disease.

Liu YC, Stone K, van Rhee F.

Expert Rev Hematol. 2014 Oct;7(5):545-57. doi: 10.1586/17474086.2014.946402. Epub 2014 Aug 9.

PMID:
25110138
16.

Multicentric Castleman's disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient.

Kofteridis DP, Tzagarakis N, Mixaki I, Maganas E, Xilouri E, Stathopoulos EN, Eliopoulos GD, Gikas A.

AIDS. 2004 Feb 20;18(3):585-6. No abstract available.

PMID:
15090823
17.

Interleukin-6 gene expression in Castleman's disease.

Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D.

Blood. 1991 Dec 1;78(11):2923-30.

18.

Dose selection of siltuximab for multicentric Castleman's disease.

Mayer CL, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, Qin X, Davis HM, Puchalski TA.

Cancer Chemother Pharmacol. 2015 May;75(5):1037-45. doi: 10.1007/s00280-015-2720-0. Epub 2015 Mar 18.

PMID:
25784388
19.

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Patel M, Ikeda S, Pilat SR, Kurzrock R.

JAMA Dermatol. 2017 May 1;153(5):449-452. doi: 10.1001/jamadermatol.2016.5554.

PMID:
28241173
20.

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F.

Clin Cancer Res. 2013 Jul 1;19(13):3659-70. doi: 10.1158/1078-0432.CCR-12-3349. Epub 2013 May 9.

Supplemental Content

Support Center